Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 160-161

  Nosari, Annamaria ^a   Caimi, Teresa Maria ^a   Zilioli, Vittorio ^a   Molteni, Alfredo ^a   Mancini, Valentina ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; D DIMER; FRESH FROZEN PLASMA; HYBRID PROTEIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PROMYELOCYTIC LEUKEMIA PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ADULT; ANEMIA; ANTIBIOTIC THERAPY; APHASIA; BLOOD CELL COUNT; BLOOD CLOTTING; BONE MARROW; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; MAINTENANCE THERAPY; MALE; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE; OCCIPITAL CORTEX; PARIETAL CORTEX; PARTIAL THROMBOPLASTIN TIME; PETECHIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; PYREXIA IDIOPATHICA; RETINA HEMORRHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; VISUAL DISORDER; VOMITING;

ADULT; CEREBRAL HEMORRHAGE; FACTOR VIIA; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84855458559     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.605189     Document Type: Letter

References (10)

1. S anz MA, Lo Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495-503.
2. Micol JB, Raff oux E, Boissel N, et al. Do early events excluding patients with acute promyelocytic leukemia from trial enrollement modify treatment evaluation? Real-life management of 100 patients referred to the University Hospital Saint Louis between 200 and 2010. Blood 2010;116(Suppl. 1): Abstract 473.
3. Park JH, Panageas KS, Schymura MJ, et al. A population-based study in APL suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: data from Surveillance, Epidemiology, and End Results (SEER) program and the New York State Cancer Registry in the United States between 1992-2007. Blood 2011 June 8. [Epub ahead of print]
4. L o Coco F, Avvisati G, Vignetti M, et al. Front-line treament of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidations for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA group. Blood 2010;116:3171-3179.
5. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant acrtivated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358:2127-2137. (Pubitemid 351679599)
6. Brenner B, Hoff man R, Balashv D, et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Th romb Hemost 2005;1:554-557.
7. F ranchini M, Veneri D, Lippi G. The potential role of recombinant activated factor VII in the management of critical hematooncological bleeding : a systematic review. Bone Marrow Transplant 2007;39:729-735. (Pubitemid 46901970)
8. Z ver S, Andoljsek D, Cernelc P. Eff ective treatment of lifethreatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004;72:455-456. (Pubitemid 38703541)
9. ZulfikarB, Kayiran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coag Fibrinolysis 2004;15: 261-263. (Pubitemid 38561555)
10. A limoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in APL. Am J Hematol 2006;81:720 (Pubitemid 44306834)